GSK shares hit as Advair generic threat grows in US
Chances of cheaper versions of the $8 billion-a-year seller being launched in the world's biggest market were increased by a draft guidance document from the Food and Drug Administration (FDA) setting out requirements for generic versions of the …
UPDATE 1-GSK shares hit as Advair generic threat grows in U.S.
GSK shares hit as Advair generics edge closer in US
View full post on world asthma day – Google News